Aerie Pharmaceuticals, Inc. (AERI): Price and Financial Metrics
Aerie Pharmaceuticals, Inc. (AERI)
Today's Latest Price: $12.75 USD
0.36 (2.91%)
Updated Dec 2 4:00pm
Add AERI to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
Ranked of 240 in Medical - Pharmaceuticals
See all "A" rated Strong Buy stocks
AERI Stock Summary
- With a one year PEG ratio of 147.91, Aerie Pharmaceuticals Inc is expected to have a higher PEG ratio (a measure of how expensive a stock is relative to its expected earnings growth) than 80.37% of US stocks.
- With a price/sales ratio of 6.98, Aerie Pharmaceuticals Inc has a higher such ratio than 79.88% of stocks in our set.
- Revenue growth over the past 12 months for Aerie Pharmaceuticals Inc comes in at 39.25%, a number that bests 87.43% of the US stocks we're tracking.
- Stocks that are quantitatively similar to AERI, based on their financial statements, market capitalization, and price volatility, are DMRC, CLXT, ARLO, TRXC, and PSTG.
- AERI's SEC filings can be seen here. And to visit Aerie Pharmaceuticals Inc's official web site, go to www.aeriepharma.com.
AERI Stock Price Chart Interactive Chart >
AERI Price/Volume Stats
| Current price | $12.75 | 52-week high | $26.26 |
| Prev. close | $12.39 | 52-week low | $9.01 |
| Day low | $12.15 | Volume | 265,744 |
| Day high | $12.85 | Avg. volume | 849,626 |
| 50-day MA | $11.58 | Dividend yield | N/A |
| 200-day MA | $13.34 | Market Cap | 596.89M |
Aerie Pharmaceuticals, Inc. (AERI) Company Bio
Aerie Pharmaceuticals is a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The company was founded in 2005 and is based in Irvine, California.
Loading social stream, please wait...